Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01032070 · ClinicalTrials.gov registry record · Phase 2
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
A Phase 2 study, sponsored by OSI Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01032070 is a Phase 2 study that was terminated before completion, run by OSI Pharmaceuticals. The registered enrollment target is 25 participants.
The verdict
NCT01032070, a Phase 2 study, was terminated before completion, sponsored by OSI Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a phase 2 study to evaluate the efficacy of single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma.
Interventions
- DRUG etoposide
- DRUG erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2010-09-27 |
| Est. Completion | 2012-11-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01032070
The ClinicalTrials.gov registry entry for NCT01032070 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OSI Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which etoposide is the first listed.
NCT01032070 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01032070 about?
NCT01032070 is a clinical study titled "Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma". This is a phase 2 study to evaluate the efficacy of single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma.
What is the current status of trial NCT01032070?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2010-09-27. Estimated completion is 2012-11-26.
What interventions are being tested in trial NCT01032070?
The interventions under investigation include: etoposide (DRUG), erlotinib (DRUG).
Who is sponsoring clinical trial NCT01032070?
This trial is sponsored by OSI Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.